CytRx Corp. (CYTR)

0.61
0.01 1.67
NASDAQ : Health Technology
Prev Close 0.60
Open 0.61
Day Low/High 0.59 / 0.61
52 Wk Low/High 0.33 / 2.18
Volume 109.25K
Avg Volume 138.70K
Exchange NASDAQ
Shares Outstanding 33.64M
Market Cap 20.18M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
CytRx Announces The Publication Of A Peer-Reviewed Case Report Documenting Tamibarotene’s Successful Elimination Of Recurrent Advanced-Stage Leukemia

CytRx Announces The Publication Of A Peer-Reviewed Case Report Documenting Tamibarotene’s Successful Elimination Of Recurrent Advanced-Stage Leukemia

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of...

CytRx Receives Shares Of ADVENTRX Pharmaceuticals In SynthRx Transaction

CytRx Receives Shares Of ADVENTRX Pharmaceuticals In SynthRx Transaction

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, has received approximately 163,000 shares of common stock in ADVENTRX Pharmaceuticals, Inc.

CytRx Announces The Presentation Of Bafetinib Study Results At The American Academy For Cancer Research (AACR) Annual Meeting

CytRx Announces The Presentation Of Bafetinib Study Results At The American Academy For Cancer Research (AACR) Annual Meeting

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib...

CytRx Begins Phase 1b Clinical Trial With INNO-206 In Patients With Advanced Solid Tumors

CytRx Begins Phase 1b Clinical Trial With INNO-206 In Patients With Advanced Solid Tumors

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the...

CytRx Reports 2010 Financial Results

CytRx Reports 2010 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

CytRx To Present At The ROTH Capital Partners 23rd Annual OC Growth Stock Conference

CytRx To Present At The ROTH Capital Partners 23rd Annual OC Growth Stock Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A.

CytRx To Receive Shares Of ADVENTRX Pharmaceuticals In Exchange For 19% Stake In SynthRx

CytRx To Receive Shares Of ADVENTRX Pharmaceuticals In Exchange For 19% Stake In SynthRx

CytRx Corporation (Nasdaq: CYTR) today announced that under terms of a definitive agreement for the acquisition of SynthRx, Inc.

CytRx’s Bafetinib Demonstrates Ability To Prevent Cancer-Related Bone Loss

CytRx’s Bafetinib Demonstrates Ability To Prevent Cancer-Related Bone Loss

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in...

CytRx To Present At The 13th Annual BIO CEO & Investor Conference

CytRx To Present At The 13th Annual BIO CEO & Investor Conference

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A.

CytRx Raises $7 Million From Sale Of Remaining Equity Interest In RXi Pharmaceuticals

CytRx Raises $7 Million From Sale Of Remaining Equity Interest In RXi Pharmaceuticals

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has raised approximately $7 million from the sale of its remaining equity interest in publicly traded RXi...

CytRx To Present At The Biotech Showcase 2011 Conference

CytRx To Present At The Biotech Showcase 2011 Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A.

CytRx Announces Compliance With NASDAQ's Minimum Bid Requirement

CytRx Announces Compliance With NASDAQ's Minimum Bid Requirement

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, reported that as of the close of the market on December 3, 2010, CytRx is in compliance with all NASDAQ listing qualifications...

CytRx’s INNO-206 Safely Delivers High-Dose Doxorubicin To Human Tumors In Animal Model Of Multiple Myeloma

CytRx’s INNO-206 Safely Delivers High-Dose Doxorubicin To Human Tumors In Animal Model Of Multiple Myeloma

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, announced positive study results indicating that INNO-206, a tumor-targeting pro-drug formulation of the commonly prescribed...

CytRx Initiating Phase 2b Clinical Trial With Tamibarotene In Advanced Lung Cancer

CytRx Initiating Phase 2b Clinical Trial With Tamibarotene In Advanced Lung Cancer

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in...

CytRx Initiates Pharmacokinetic Clinical Trial With Bafetinib In Brain Cancer

CytRx Initiates Pharmacokinetic Clinical Trial With Bafetinib In Brain Cancer

CytRx Corporation (Nasdaq:CYTR) a biopharmaceutical company specializing in oncology, today announced initiation of a pharmacokinetic clinical trial with its oncology drug candidate bafetinib in patients with...

CytRx Reports Third Quarter Financial Results

CytRx Reports Third Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2010, and provided a business update.

CytRx Awarded $735,000 Grant Under The Qualifying Therapeutic Discovery Project Program

CytRx Awarded $735,000 Grant Under The Qualifying Therapeutic Discovery Project Program

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has been awarded a nontaxable grant of approximately $735,000 related to its INNO-206, tamibarotene and...

CytRx To Present At Rodman & Renshaw 12th Annual Healthcare Conference

CytRx To Present At Rodman & Renshaw 12th Annual Healthcare Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.

CytRx Initiates Phase 2 Clinical Trial With Bafetinib In Advanced Prostate Cancer

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to...

CytRx Reports 2010 Second Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

CytRx’s Tamibarotene Eradicates Former NBA Player’s Aggressive, Advanced-Stage Leukemia

CytRx’s Tamibarotene Eradicates Former NBA Player’s Aggressive, Advanced-Stage Leukemia

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that an advanced form of acute promyelocytic leukemia, or APL, has been eradicated in former NBA player Ray...

CytRx’s Tamibarotene Eradicates Cancer In Advanced Acute Promyelocytic Leukemia After Failure Of Other Therapies

CytRx’s Tamibarotene Eradicates Cancer In Advanced Acute Promyelocytic Leukemia After Failure Of Other Therapies

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete...

CytRx Announces Substantial Progress With Its Bafetinib Clinical Trials Program

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in...

CytRx Set To Join The Russell 3000 Index

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is set to join the Russell 3000 ® Index, according to a preliminary list of additions posted June 11...

CytRx Announces Issuance Of Key U.S. Patent Covering Bafetinib

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the granting by the U.

CytRx To Present At The Jefferies 2010 Global Life Sciences Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that David J.

CytRx Initiates Phase 2 Clinical Trial With Bafetinib In B-cell Chronic Lymphocytic Leukemia

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its...

Research Trial Evaluating CytRx’s Bafetinib In Brain Tumor Model To Be Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition...

CytRx To Present At The Rodman & Renshaw Annual Global Healthcare Conference In London

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that CytRx President and CEO Steven A.

CytRx Reports 2010 First Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three-month period ended March 31, 2010.

TheStreet Quant Rating: D- (Sell)